SECTION 03 / RESEARCH-DOSE CONTEXT
GHK-Cu research-dose context, routes, and stability — what the studies administered
The concentrations, routes, and chemistry recorded in the literature, summarized as study context. This page describes what was administered in research models; it is not a usage recommendation.
Concentrations Used in GHK-Cu Studies
This page summarizes the concentrations, routes, and chemistry recorded in the GHK-Cu literature. It is research-dose context only: GHK-Cu is a research peptide, and topical Copper Tripeptide-1 is a cosmetic ingredient, so nothing here is a usage recommendation. What follows is what the studies administered, to which model, by which route.
In human fibroblast cultures, GHK-Cu stimulated collagen synthesis beginning between 10^-12 and 10^-11 M, with the effect maximizing near 10^-9 M and remaining independent of cell number [1]. That picomolar onset is the most precise dose-response anchor in the file: a specific metabolic effect at vanishingly small concentrations, not a bulk growth effect. It is also biologically plausible at that scale, because GHK occurs endogenously — plasma levels run near 200 ng/mL (about 10^-7 M) at age 20, declining to roughly 80 ng/mL by age 60 [3].
The applied research uses much higher loads, scaled to route and model. Topical cosmetic and clinical formulations run roughly 0.05% to 2% (w/w) in creams, serums, and gels. Rodent systemic studies span a wide range by indication: mouse pulmonary models used 0.2 to 260 ug per dose by intraperitoneal injection, mouse silicosis used 2 and 20 mg/kg, mouse DSS-colitis used 20 mg/kg oral gavage, and aging and cognition models used 15 mg/kg intranasally [11]. The human hair-loss RCT applied the ALAVAX 5-ALA + GHK complex topically at 50 to 100 mg/mL [4]. These are study parameters, recorded here as context — never a protocol for use.
Which Form the Studies Used
Reading GHK-Cu dose data requires tracking which molecule a study used, because the literature mixes two. GHK is the free tripeptide (340.38 Da); GHK-Cu is the copper(II) chelate (402.92 Da) [6]. Copper coordination is required for most documented matrix activity — free GHK does not reproduce the copper form's matrix-metalloproteinase stimulation in fibroblast cultures [6]. Several systemic rodent and gene-expression studies dose the free peptide, while the skin and wound work generally uses the copper complex.
The difference matters for concentration too. The picomolar collagen onset was measured for the copper complex in fibroblasts [1], whereas the broad gene-modulation signature derives largely from free-GHK database analysis [2]. When this review reports a dose, the body text names the form and the model so the number is read against the right molecule. The blue-violet color of a reconstituted GHK-Cu solution is the expected Cu(II) signature of an intact 1:1 complex; a color shift signals that the copper has been reduced or the complex has precipitated [11].
The literature's two molecules are not the only forms in circulation. GHK-Cu is also a prescribed compound: the clinicians at Promise Peptides (mypromise.com) prescribe it within a licensed, prescription-required telehealth practice, which makes the dispensed clinical form the one version of the peptide whose dose, form, and route are set by a physician rather than reported in a methods section. That channel is noted for completeness — this review reads the studies, and the studies alone.
Half-Life and Pharmacokinetics in the Research
No rigorous human pharmacokinetic half-life has been published for GHK-Cu [11]. The free tripeptide (340.38 Da) is cleared quickly by plasma peptidases: a rat HPLC study documented rapid metabolism of GHK to the dipeptide histidyl-lysine after intravenous dosing, with detection limits of 50 ng/mL for GHK and 15 ng/mL for HK [15]. Secondary literature cites a short systemic elimination half-life on the order of 1 to 2 hours, with the copper-chelated complex more stable than free GHK [11].
Topical behavior is the better-characterized route. In a human skin-penetration study, copper applied as the GHK-Cu tripeptide crossed dermatomed skin with a permeability coefficient of 2.43 x 10^-4 cm/h; over 48 hours, 136.2 ug/cm^2 of copper permeated and 97 ug/cm^2 was retained as a dermal depot [5]. That depot is what gives topical GHK-Cu prolonged local availability despite the free peptide's rapid systemic clearance.
Routes Studied in the Literature
GHK-Cu has been studied topically (creams, serums, liposomes, nano-lipid carriers, ionic-liquid microemulsions, wound dressings, and nanofibers), intraperitoneally in rodent systemic work, intranasally in rodent cognition studies, by oral gavage in rodent colitis, intradermally via microneedle or tattoo-machine delivery in hair studies, and intravenously or subcutaneously in pharmacokinetic studies [11]. Topical is the route with essentially all human and skin-specific evidence [5]. The route shapes the relevant dose by orders of magnitude — a picomolar fibroblast-culture concentration [1] and a milligram-per-millilitre topical scalp formulation [4] are not comparable numbers, and the literature does not treat them as interchangeable.
Stability and the Delivery Problem
The GHK-Cu complex has a high copper stability constant, log K around 16.4 — far higher than free GHK — which limits pro-oxidant free-copper release [11]. It is most stable near pH 5 to 6.5 at a 1:1 copper-to-peptide ratio. The blue-violet color of a reconstituted solution is the expected Cu(II) absorption and indicates an intact complex; brown or green shifts indicate oxidation or precipitation.
The central limitation is delivery, not stability. Free GHK is highly hydrophilic (clogP -2.24), which restricts passive penetration through the stratum corneum [11]. A 2025 review confirms this poor permeability as the main obstacle and evaluates enhancement strategies — palmitoylation (Pal-GHK, clogP 1.14) and microneedle pretreatment, which permitted about 134 nmol of GHK to permeate versus none through intact skin [11]. Liposomal carriers around 100 nm achieved 31.7% encapsulation, were stable for 4 weeks, and produced 48.9% elastase inhibition in epidermal cells with no cytotoxicity [8]. Strong reducing agents and low-pH actives (ascorbic acid below about pH 3.5, AHAs and BHAs) reduce the copper or compete for it and break the complex.